T1	Condition 10 17	allergy
T2	Drug 21 29	apatinin
T3	Drug 41 51	excipients
*	OR T2 T3
T4	Scope 21 51	apatinin and or its excipients
R1	Has_scope Arg1:T1 Arg2:T4	
T5	Condition 54 66	Hypertension
T6	Condition 68 87	high blood pressure
R2	Subsumes Arg1:T5 Arg2:T6	
T7	Qualifier 105 124	controlled by drugs
T8	Drug 119 124	drugs
R3	multi Arg1:T7 Arg2:T8	
R4	Has_qualifier Arg1:T5 Arg2:T7	
T9	Negation 98 101	not
R5	Has_negation Arg1:T7 Arg2:T9	
T10	Qualifier 140 146	active
T11	Condition 147 157	hemorragge
T12	Condition 159 164	ulcer
T13	Condition 166 188	intestinal perforation
T14	Condition 190 212	intestinal obstruction
T15	Condition 217 230	major surgery
T16	Temporal 231 252	no older than 30 days
*	OR T15 T14 T13 T12 T11
R6	Has_qualifier Arg1:T11 Arg2:T10	
T17	Scope 140 230	active hemorragge, ulcer, intestinal perforation, intestinal obstruction, or major surgery
R7	Has_temporal Arg1:T17 Arg2:T16	
T18	Measurement 255 259	NYHA
T19	Value 260 266	III-IV
R8	Has_value Arg1:T18 Arg2:T19	
T20	Condition 267 281	heart function
T21	Qualifier 286 292	severe
T22	Condition 293 300;310 323	hepatic insufficiency
T23	Condition 304 323	renal insufficiency
T24	Qualifier 325 332	Grade 4
R9	Subsumes Arg1:T21 Arg2:T24	
T25	Scope 293 323	hepatic or renal insufficiency
R10	Has_qualifier Arg1:T25 Arg2:T21	
*	OR T20 T25
R11	AND Arg1:T20 Arg2:T18	
T26	Observation 357 393	factors that affect oral medications
T27	Condition 403 424	difficulty swallowing
T28	Condition 426 432	nausea
T29	Condition 434 442	vomiting
T30	Condition 444 460	chronic diarrhea
T31	Condition 465 487	intestinal obstruction
*	OR T30 T31 T29 T28 T27
T32	Scope 403 487	difficulty swallowing, nausea, vomiting, chronic diarrhea and intestinal obstruction
R12	Has_context Arg1:T32 Arg2:T26	
T33	Pregnancy_considerations 490 683	Pregnant or lactating women, or women of child-bearing potential who have planned a pregnancy, or male and female patients who do not agree to practice adequate contraception during this study;
T34	Observation 705 712	history
T35	Condition 730 735	abuse
T36	Drug 716 729	psychotropics
R13	AND Arg1:T35 Arg2:T36	
R14	Has_temporal Arg1:T35 Arg2:T34	
T37	Condition 766 782	mental disorders
T38	Non-representable 736 752	and can not quit
*	OR T35 T37
T39	Competing_trial 785 852	Participation in other drug clinical trial within the last 4 weeks;
T40	Drug 873 889	VEGFR inhibitors
T41	Drug 898 907	sorafenib
T42	Drug 912 921	sunitinib
*	OR T41 T42
T43	Scope 898 921	sorafenib and sunitinib
R15	Has_scope Arg1:T40 Arg2:T43	
T44	Non-query-able 924 1058	Presence of comorbidities that seriously affect the patient's safety or ability to complete the study, in the investigator's judgment;
T45	Condition 1081 1089	tolerate
T46	Negation 1077 1080	not
T47	Drug 1090 1098	apatinib
R16	Has_negation Arg1:T45 Arg2:T46	
R17	AND Arg1:T45 Arg2:T47	
T48	Non-query-able 1180 1255	Patients that are considered ineligible for this study by the investigator.
